PANCREATIC DUCTAL ADENOCARCINOMA

This study tests whether giving a single dose of chemotherapy directly into the liver artery, before standard treatment, is safe and feasible for people with localized pancreatic cancer. It includes 20 adults whose cancer can be surgically removed. The goal is to see if this adde…

This early-phase study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with pancreatic, lung, or co…

This study compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the usual two-drug combination (nab-paclitaxel plus gemcitabine) in people with metastatic pancreatic cancer that has spread to other parts of the body. Only patients w…

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This early-phase trial tests whether adding the drug ivosidenib to standard chemotherapy can help shrink pancreatic tumors before surgery. About 16 people with resectable pancreatic cancer will take part. The main goal is to find the safest dose and see how well the combination w…

This study tests whether giving chemotherapy both before and after surgery helps people with pancreatic cancer live longer compared to chemotherapy only after surgery. About 378 patients with resectable pancreatic cancer will be randomly assigned to one of two treatment schedules…

This early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the s…

This study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor helps patients live longer. About 845 adults having surgery for suspected pancreatic or related cancers will be randomly assigned to one of three groups: washing with wa…

This study tests a combination of two experimental drugs (AGEN1423 and botensilimab) with or without standard chemotherapy in people with advanced pancreatic cancer that has worsened after at least one prior treatment. The goal is to see if the combination can shrink tumors or sl…

This study tests whether using a tiny heat probe (radiofrequency ablation) guided by an ultrasound camera can help people with inoperable pancreatic cancer live longer. About 108 adults whose cancer cannot be removed by surgery will either receive standard care or the heat probe …

This study tests whether adding the experimental drug navlimetostat to standard chemotherapy can help people with a specific type of advanced pancreatic cancer (one with a missing MTAP gene). About 470 adults who have not had prior treatment for metastatic disease will receive ei…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This early-stage study tests a new drug (RO7496353) combined with an immunotherapy (checkpoint inhibitor) and sometimes chemotherapy in people with advanced lung, stomach, or pancreatic cancer. The main goal is to check safety and find the right dose. About 102 participants will …

This early-phase study tested a vaccine therapy given directly into the tumor along with a growth factor to boost the immune system in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effe…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or can't be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the drug combo can shrink tum…

This study tests a new pill called IPN01194 in adults with advanced solid tumors (cancers that have spread). The goal is to find the right dose and check if it is safe and shrinks tumors. About 36 people with melanoma, colorectal, pancreatic, or head and neck cancers will take th…

This study tests how well and how safely the drug glipizide lowers blood sugar in people with pancreatic cancer. About 29 adults with active pancreatic cancer and high blood sugar will take glipizide, and their glucose levels will be measured before and after starting the drug. T…

This study tests a new drug called chiauranib combined with two standard chemotherapies as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The drug works by blocking key processes that help tumors grow and spread. The trial includes…

This study tests whether a combination of three drugs (paricalcitol, hydroxychloroquine, and losartan) can safely modify the supportive tissue around pancreatic tumors before surgery. About 20 adults with resectable pancreatic cancer will take these drugs for at least 4 weeks bet…

This early-phase trial tests whether transferring healthy gut bacteria from donor stool can help control pancreatic cancer. Ten patients scheduled for tumor-removal surgery will receive the transplant to see if it is safe and affects the disease. The study is currently suspended.

This study tests a new drug (AZD0171) combined with two other treatments (durvalumab and chemotherapy) in people with advanced pancreatic cancer that has spread. The goal is to see if the combination is safe and helps control the cancer longer. About 126 participants will receive…

This study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with an antibody called ezabenlimab. The goal is to find a safe dose and see if the combination ca…

This study tests an 8-week program of nutrition, exercise, and mental support for people with pancreatic or esophageal cancer before they have surgery. The goal is to see if this program helps patients complete their planned treatments. The study includes 9 participants and focus…

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (lung, kidney, head and neck, colorectal, pancreatic, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety and find the right dose. Abo…

This early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors (such as liver, pancreatic, breast, and ovarian cancers). The goal is to see if the drug is safe and can shrink tumors. Participants receive the drug by IV, alone or w…

This study tests whether combining a new drug (ZN-c3) with standard chemotherapy (gemcitabine) can help control advanced pancreatic cancer that has stopped responding to earlier treatment. It involves 12 adults whose cancer has spread or cannot be removed. The main goal is to see…

This early study tests whether adding three cholesterol-lowering drugs (atorvastatin, ezetimibe, and evolocumab) to standard chemotherapy can slow or stop pancreatic cancer growth. Cancer cells need lots of cholesterol to grow, and this approach aims to starve them. The trial inc…

This study aimed to test a new type of PET scan that uses two substances to find cancer cells with a marker called CA19-9. It was designed for people with pancreatic, bladder, or other gastrointestinal cancers. However, the study was withdrawn before any participants were enrolle…

This study is working on a new way to detect pancreatic cancer early using a simple urine and blood test. Researchers are collecting samples from 3500 people, both with and without pancreatic disease, to see if a panel of biomarkers can accurately identify cancer. The goal is to …

This study tests whether a practical diet and exercise program can help people with certain pancreatic cysts lower their risk of developing pancreatic cancer. Twenty-four adults with a type of pancreatic cyst called IPMN (larger than 15 mm) and who are overweight will follow a 6-…

This study looks at whether ketorolac, a common anti-inflammatory drug, is safe and can help stabilize or increase weight in people with advanced pancreatic cancer who are experiencing cachexia (severe weight loss). About 28 participants will take the drug four times daily for fi…

This study is a registry that collects information from 2,000 people who have had pancreatic surgery for benign or malignant tumors. The goal is to track surgical methods, complications, and long-term results to improve quality of care and support future research. No new treatmen…

This study is creating a large database of people at high risk for pancreatic cancer, including those with cysts, genetic conditions, or other risk factors. The goal is to track their health over time to find better ways to detect the disease early or even prevent it. About 317 p…

This study tests whether a new PET imaging tracer called 18F-FAC can show how much standard chemotherapy gets into pancreatic tumors. About 30 adults with pancreatic cancer will get a PET scan before starting treatment. The goal is to gather information, not to treat the disease …

This study collects blood samples from 102 people with non-small cell lung cancer, colorectal cancer, or pancreatic cancer to track cancer-related DNA changes over the course of their standard treatment. Researchers aim to see if these blood-based markers can help predict tumor r…

This study is building a database of information from 600 people who have a BRCA or PALB2 gene mutation and pancreatic cancer, along with their close relatives. The goal is to collect medical data and biological samples to help researchers better understand why pancreatic cancer …